Bone Mineral Density
Investigators examined the effect of consuming a Mediterranean-style diet for 1 year on inflammatory response and bone health in the elderly.
The risk for bone fractures was not increased in patients with type 2 diabetes using empagliflozin compared with placebo or glimepiride.
High levels of serotonin are predictive of an increased risk for hip fracture, nonvertebral osteoporotic fracture, and incident fractures in older men.
Romosozumab increased bone mineral density in postmenopausal women through increased bone formation and decreased bone resorption.
Men with accelerated bone loss have lower estimated bone strength, poorer trabecular microarchitecture, and thinner cortices compared with men without accelerated bone loss.
Investigators sought to determine whether both restrictive and purging types of anorexia nervosa effect bone metabolism.
Gastric bypass surgery can have damaging effects on bone mass as early as 6 months postoperatively.
Routine vitamin D and calcium supplementation in older adults is not supported for lowering the incidence of osteoporosis-related fractures.
Tocilizumab treatment for 2 years was shown to reduce levels of bone loss in patients with ACPA-positive RA.
Growth hormone therapy may reduce the risk for fracture in patients with osteoporosis.
The UK National Osteoporosis Guideline Group released updated guidelines for the prevention of fragility fracture in postmenopausal women and in men aged 50 years or older.
Total hip BMD was associated with heart failure risk in black and non-black men, with an interaction by race.
Researchers compared the efficacy of dual-energy x-ray absorptiometry with lateral x-ray in assessing vertebral fractures.
This week, a phase III trial for investigational drug voclosporin for lupus nephritis treatment was approved, prolonged insomnia may lead to less robust bone formation — causing osteoporosis and bone fractures — and researchers found that women who drink a moderate amount of alcohol daily have a reduced risk of developing systemic lupus erythmatosus.
Three-year fracture study examines the effects of osteoporosis drug denosumab on fractures, bone mineral density, and bone turnover markers in postmenopausal women with osteoporosis.
Prospective observational cohort study examines association between post-ICU administration of anti-fracture therapy or glucocorticoids and longitudinal changes in bone mineral density.
Testosterone treatments help improve volumetric bone mineral density and bone strength in elderly men with low testosterone.
The trabecular bone score may provides an acute, albeit indirect, measurement of bone quality in patients with type 2 diabetes.
Study examines the predictive value for vertebral fractures of bone mineral density and bone turnover markers after a 5-year drug holiday.
Long-term tenofovir treatment for hepatitis B infection is linked with abnormal phosphorus metabolism in a recent study.
Lorraine Fitzpatrick, MD, discusses updated results from the ACTIVE phase 3 clinical trial.
Higher Trabecular Bone Scores were found in postmenopausal women taking hormone replacement therapy compared with women who had never used hormone therapy.
DMARDs have been shown to be effective in halting progressive bone loss in rheumatoid arthritis.
Pediatric and adolescent patients who used stimulants to treat ADHD were found to have low bone density and bone mineral content.
Kenneth Saag, MD, president of the National Osteoporosis Foundation (NOF), co-chair of the National Bone Health Alliance, and Rheumatology Advisor advisory board member, reports on the recent changes that have led to the current state of osteoporosis treatment in the US.
Findings showing that sedentary time was not significantly linked to bone mineral density weaken the previous association between physical activity and bone mineral density.
The use of ARBs was associated with lower incidence of non-vertebral fractures than ACE inhibitors or CCBs.
Denosumab treatment led to significant increases in BMD at the lumbar spine and total hip at 12 months as compared to risedronate, both in patients receiving continuing glucocorticoid therapy and those just starting glucocorticoid therapy.
To better predict bone loss during the menopausal transition, researchers created the bone balance index using bone turnover markers to measure net bone formation.
Interval changes in bone mineral density (BMD) detected by dual-energy x-ray absorptiometry (DXA) are associated with fracture risk in women starting osteoporosis treatment
Rheumatology Advisor Articles
- Efficacy of ABT-122 Maintained in Psoriatic Arthritis, Rheumatoid Arthritis at 36 Weeks
- Comorbid Fibromyalgia Influences Disease Activity, Quality of Life in Axial Spondyloarthritis
- Knee Load Associated With Increased Walking Pain in Osteoarthritis
- Pain Catastrophizing Decreases in Rheumatoid Arthritis After DMARD Initiation
- CVD Prevention Measures Inadequate in Patients With Inflammatory Joint Diseases
- Genetic Screening May Predict Osteoporosis, Fracture Risk
- Exploring the Clinical Implications of Cannabinoid Use in Rheumatoid Arthritis
- Diagnosing Lyme Disease in Children With Neuropsychiatric Illness
- Predicting Primary Nonresponse to Methotrexate in Rheumatoid Arthritis
- Prednisone, Prednisolone Does Not Adversely Affect Bone Mineral Density in RA
- Sulfasalazine Reduces Pneumocystis Pneumonia Risk in Rheumatoid Arthritis
- DPP-4 Inhibitors and Incidence of Rheumatoid Arthritis in Type 2 Diabetes
- Response to Certolizumab Pegol at 12 Weeks Predicts Long-Term RA Outcomes
- Performance Phenotypes of Lumbar Spinal Stenosis and OA With Accelerometry Data
- Characteristics of Early-Onset SLE Distinguished From Mimicking Conditions